WayPoint Biomedical Holdings, Inc., through its wholly owned subsidiary, WayPoint Biomedical, Inc., engages in the development and marketing of diagnostic tests and devices for screening and monitoring human health, fitness, and environment. It offers a drink spiking test, the Drink Detective, used to detect date rape drugs, including Ketamine, GHB, and Benzodiazapines; and Health Essist tests for cocaine and marijuana detection. The company also develops and commercializes test kits for detection against possible explosive devices, biowarfare/bioterrorism agents, and the detection of weapons of mass destruction. In addition, it provides Frontline Explosive Test Kit for the detection of explosive residues. The company offers its products to the over-the-counter diagnostic self-testing, the diagnostic point of care, and the homeland security and defense markets. WayPoint Biomedical Holdings was founded in 2004 and is based in Huntington Beach, California.
0 transactions — 0 buys and 0 sales reported by WayPoint Biomedical Holdings, Inc. executives.
0 institutional funds report a position on WYPH in their latest SEC quarterly filing.
Beyond raw data, we aggregate and score every smart money signal to give you a unique view.
8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.
Detection of clustered purchases or sales by several executives in the same stock.
Berkshire, Pershing Square, Tiger Global, Bridgewater and other reporting funds.
NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.
Spot marked changes in search interest around the stocks being followed.
Create your watchlist and receive a brief of events affecting your tickers.
This public page only shows a preview. The full analysis of WYPH on the Kairos Insider dashboard includes:
Free signup · Pro €19/month or €190/year